Efficacy of Sufoof-i-Tabkheer and Arq-i-Badiyan in Dyspepsia- An open labelled single Arm Clinical Study

ational Institute of Unani Medicine0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Symptoms persist at least for 1 month with moderate to severe symptoms (score > 4 on the 7 point Global overall symptoms (GOS) scale).

•1.Patients age below 18 and above 50 year
•2.Patients with severe systemic and metabolic diseases
•3.History of angina pectoris
•4.Pregnant and lactating women
•5.Patients with alarming symptoms (unintentional weight loss, recurrent vomiting, dysphasia, hematemesis, Malena, fever, jaundice, anemia.
•6.History of any serious gastrointestinal disease including peptic ulcer, malignancy, dysmotility.
•7.Previous endoscopic diagnosis of erosive gastro-esophagitis or Barrett esophagus.
•8.Gastrointestinal surgery within 30 days.
•9.Hemoglobin <9g/dl, Total leukocyte count <3000/ul, Platelet count <75000/ul, AST & ALT >120 IU/L, Serum creatinine >1.5 mg/dl, Occult blood in stool.
•10.Treatment history of NSAIDs, H2 receptors blockers, PPI, Prokinetic drugs, sucralfate or other ulcer healing agents within 15 days prior to enrolment.
•11.Concomitant use of psychotropic drugs.
•12.History of alcohol consumption

发起方

ational Institute of Unani Medicine